Aradigm (ARDM) Stock Price, News & Analysis

Company Overview

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.15 to $0.38
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 97,091 shs
• Market Capitalization: $761 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARDM Stock Analysis - Frequently Asked Questions

How were Aradigm's earnings last quarter?

Aradigm Co. (NASDAQ:ARDM) posted its quarterly earnings results on Thursday, November, 15th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The firm earned $0.28 million during the quarter.

What other stocks do shareholders of Aradigm own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aradigm investors own include Amarin (AMRN), Anavex Life Sciences (AVXL), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), Vaxart (VXRT), Aduro Biotech (ADRO) and Altimmune (ALT).

Company Calendar

• Last Earnings: 11/15/2018
• Today: 7/15/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical Equipment
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ARDM
• CIK: 1013238
• Web: www.aradigm.com
• Phone: 510-265-9000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.70 million
• Net Margins: -374.80%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -374.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: $14.47 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.83) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 15,220,000
• Free Float: N/A
• Market Cap: $761 thousand
• Optionable: Optionable
• Beta: 1.57